Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378991 | 0.89 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL14541889 | 0.86 | SCD (0.81) | SCDDCTPP1 | |
| SCHEMBL1378674 | 0.86 | SCD (0.93) | SCDDCTPP1 | |
| SCHEMBL3404868 | 0.85 | SCD (0.59) | SCDDCTPP1 | |
| SCHEMBL2299671 | 0.85 | SCD (0.62) | SCDDCTPP1 | |
| SCHEMBL1377032 | 0.84 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL1377723 | 0.83 | SCD (0.73) | SCDDCTPP1 | |
| SCHEMBL1380562 | 0.83 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL1379639 | 0.83 | SCD (0.85) | SCDDCTPP1 | |
| SCHEMBL1818422 | 0.82 | SCD (0.77) | SCDDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | claimed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | claimed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008135141-A1 | 2 -HETEROARYL- PYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SCD, SCD5, PYCR1 | SCD 1/4885DCTPP1 929/4885 |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SCD, SCD5, PYCR1 | SCD 1/4885DCTPP1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.